Effects of a multi-herbal extract on type 2 diabetes

Jiyoung Yeo, Young-Mi Kang, Su-In Cho, Myeong-Ho Jung*

Abstract

Background: An aqueous extract of multi-hypoglycemic herbs of *Panax ginseng* C.A.Meyer, *Pueraria lobata*, *Dioscorea batatas* Decaisne, *Rehmannia glutinosa*, *Amomum cadamomum* Linné, *Poncirus fructus* and *Evodia officinalis* was investigated for its anti-diabetic effects in cell and animal models.

Methods: Activities of PPARγ agonist, anti-inflammation, AMPK activator and anti-ER stress were measured in cell models and in *db/db* mice (a genetic animal model for type 2 diabetes).

Results: While the extract stimulated PPARγ-dependent luciferase activity and activated AMPK in C2C12 cells, it inhibited TNF-α-stimulated IKKβ/NFκB signaling and attenuated ER stress in HepG2 cells. The *db/db* mice treated with the extract showed reduced fasting blood glucose and HbA1c levels, improved postprandial glucose levels, enhanced insulin sensitivity and significantly decreased plasma free fatty acid, triglyceride and total cholesterol.

Conclusion: The aqueous extract of these seven hypoglycemic herbs demonstrated many therapeutic effects for the treatment of type 2 diabetes in cell and animal models.

Background

Caused by complex interactions of multiple factors, diabetes mellitus type 2 (type 2 diabetes) is characterized by decreased secretion of insulin by the pancreas and resistance to the action of insulin in various tissues (e.g. muscle, liver, adipose), leading to impaired glucose uptake [1]. Management of type 2 diabetes usually begins with change of diet and exercise [2] and most patients ultimately require pharmacotherapy, such as oral anti-diabetic drug (OAD) [1]. OADs include sulfonylurea, non-sulfonylurea secretagogues, biguanides (e.g. metformin), thiazolidinediones (e.g. TZD or glitazone) and glucosidase inhibitors and glucagon-like peptide-1 (GLP-1) inhibitor. All OADs, however, have adverse effects, eg weight gain with sulfonylurea, non-sulfonylurea secretagogues or TZD, edema and anemia with TZD [1].

A variety of medicinal herbal products including herbs used in Chinese medicine have beneficial effects on diabetes [3] and used as non-prescription treatment for diabetes [4]; many of these herbs have been formulated into multi-herbal preparation for enhanced effects [5].

While traditional formulae are often prescribed, their efficacy has yet to be investigated; recently, anti-diabetic multi-herbal formulae were studied and reported [6,7].

The present study reports a new anti-diabetic formula consisting of seven herbs, namely hypoglycemic cardiosides including *Panax ginseng* C.A.Meyer, *Pueraria lobata*, *Dioscorea batatas* Decaisne, *Rehmannia glutinosa* [8], *Amomum cadamomum* Linné [9], *Poncirus fructus* [10] and *Evodia officinalis* [11] which are available in South Korea. This formula’s anti-diabetic molecular mechanisms and anti-hyperglycemic effects are demonstrated in cell models and *db/db* mice respectively.

Methods

Extract preparation

The dried herbs of *Panax ginseng* C.A. Meyer (Aralia family), *Pueraria lobata* (Pea family), *Dioscorea batatas* Decaisne, *Rehmannia glutinosa* [8], *Amomum cadamomum* Linné [9], *Poncirus fructus* (Rhamnaceae) and *Evodia officinalis* DODE (Rutaceae) were purchased from Kwangmyung-dang Natural Pharmaceutical (Korea) and identified morphologically, histologically and authenticated by Professor Su-In Cho (School of Korean Medicine, Pusan National University, Beomeo-ri, Mulgeum-eup, Yangsan, Gyeongsangnam-do, 626-770, South Korea).

* Correspondence: jung0603@pusan.ac.kr
School of Korean Medicine, Pusan National University, Beomeo-ri, Mulgeum-eup, Yangsan, Gyeongsangnam-do, 626-770, South Korea
© 2011 Yeo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
National University, Korea) according to standard protocol in National Standard of Traditional Medicinal Materials of The Korean Pharmacopeia [12]. Voucher specimens of all seven species were deposited in Pusan National University, Korea.

Powders of the herbs were mixed in equal amount (200 g each) and extracted in hot-water. The extract was freeze dried to powder and melt by dimethylsulfoxide (DMSO) when used. Macelignan, an active compound of *Myristica fragrans* Houtt. (Myristicaceae), was prepared for positive control [13].

**Cell lines**

Cell lines of human embryonic kidney (HEK) 293 (CRL-1573), 3T3-L1 pre-adipocytes (CL-173), HepG2 hepatocytes (HB-8065) and C2C12 skeletal myoblast cells (CRL-1772) were obtained from the American Type Culture Collection (ATCC, USA). HEK293 and HepG2 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose (Invitrogen, USA) supplemented with 10% (v/v) fetal bovine serum (Gibco BRL, USA). The 3T3-L1 pre-adipocytes were differentiated as described previously [14]. C2C12 skeletal myoblast cells were grown in DMEM supplemented with 2% horse serum to induce differentiation into myotubes.

**Reporter assays**

The PPAR ligand-binding activity was measured with a GAL4/PPAR chimera assay and PPRE-tk-Luc reporter assay as described previously [15]. HEK293 cells were transfected with pFA-PPARγ and pFR-Luc (UAS-Gal4-luciferase) and treated with the extract, rosiglitazone (Alexis Biochemicals, USA) or macelignan at doses ranging from 2 to 10 μmol/L for 24 hours. For PPRE-tk-Luc reporter assay, HepG2 (2 × 10⁵ cells/well) were transfected with PPRE-tk-Luc and incubated with the extract, rosiglitazone or macelignan for 24 hours. The luciferase activities were then determined with a Dual-Glo Luciferase assay system kit (Promega, USA).

To determine the anti-inflammatory activities and anti-endoplasmic reticulum (ER) stress, we transfected HepG2 cells (2 × 10⁵ cells/well) with Nfkb-Luc reporter or ERSE-Luc reporter using a Cignal™ Reporter Assay kit (SABiosciences, USA). The cells were then incubated with the extract, rosiglitazone or macelignan for 24 hours. The luciferase activities were determined with a Dual-Glo Luciferase assay system kit (Promega, USA).

**Real-time RT-PCR**

We performed Real-time RT-PCR to determine the expression of adipose fatty acid-binding protein (aP2), acyl-CoA synthetase (ACS) and carnitine palmitoyltransferase-1 (CPT-1). The total RNA was extracted with TRIzol reagent (Invitrogen, USA) and subjected to reverse transcription with M-MLV Reverse Transcriptase (Promega, USA). The total RNA was then amplified (with gene-specific primers) and quantified with a fluorescence thermocycler (iQ™5, Multicolor Real-Time PCR System, Bio-Rad, USA).

**Western blot analysis**

Total proteins were extracted with PRO-PREP reagent (iNtRON Biotechnology, Korea) and immuno-blotted with the antibodies of p-AMPK, IκBα, GRP78 or p-eIF2α (Santa Cruz Biotechnology, USA) [15]. The immune complexes were identified with an enhanced chemiluminescence detection system (Amersham Biosciences, Sweden) according to the manufacturer’s instructions and in conjunction with a Fluorochem gel image analyzer (MF-Chem:BIS 3.2, Alpha Innotech, USA).

**Animal study**

Twenty-eight (28) male C57BL/KsJ-db/db mice aged 8 weeks were purchased from Jackson Laboratory (USA) and individually housed in polycarbonate cages under a 12-hour light-dark cycle at 21-23°C and 40-60% humidity. After a 2-week adaptation period, the body weight and fasting blood glucose level of the 10-week-old mice were measured. Then, the mice were equally divided into four groups (n = 7): (1) diabetic control, (2) rosiglitazone, (3) macelignan and (4) treatment (with the extract). All groups were fed a standard AIN-76 semisynthetic diet (American Institute of Nutrition) and three experimental groups (rosiglitazone, macelignan and treatment) were orally administered with rosiglitazone (10 mg/kg body weight), macelignan (15 mg/kg body weight) or the extract (150 mg/kg body weight) for three weeks. After starved for 12 hours, the mice were anesthetized with ether and their blood samples were collected from the inferior vena cava for the measurement of the blood and plasma biomarkers such as HbA1c and insulin. All animal handling during the experiments were in accordance with the Pusan National University guidelines for the care and use of laboratory animals.

**Fasting blood glucose, blood HbA1c and plasma biomarker analyses**

During the experiments, the fasting blood glucose concentration was monitored by a Glucometer (GlucoDr, Allmedicus, Korea) with venous blood drawn from the mouse tail vein after a 12-hour fast. Moreover, the blood glycosylated hemoglobin (HbA1c) collected from sacrificed mice was measured with a MicroMat™II Hemoglobin A1c Test (Bio-Rad Laboratories, USA). All blood samples obtained were centrifuged at 1000 × g for 15 min at 4°C for biochemical analysis. The plasma insulin, glucagon and C-peptide levels were measured...
with the enzyme-linked immunosorbent assay (ELISA) kits (ALPCO Diagnostics, USA).

Furthermore, the plasma lipids such as total cholesterol and triglyceride were determined with commercial kits (Sigma-Aldrich, USA) while the plasma free fatty acid (FFA) concentration was determined with an ACS (acyl-CoA synthetase)-ACOD (ascorbate oxidase) method (Wako Pure Chemical Industries, Japan).

**Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT)**

On the third week of treatment, an intraperitoneal glucose and insulin tolerance test (IPGTT and IPITT) were performed on all db/db mice after a 12-hour overnight fast. To determine the glucose and insulin tolerance, we injected the mice intraperitoneally with glucose (0.5 g/kg body weight) or insulin (2 unit/kg body weight). The glucose concentrations of blood drawn from the tail vein were determined immediately upon collection at 30, 60 and 120 min after glucose injection or at 30, 60 and 120 min after insulin injection.

**Statistical analysis**

All statistical tests were two-sided, and the level of significance was set at 0.05. All data are presented as mean ± standard deviation (SD) for all groups. Statistical analyses were performed with the SPSS, version 18 (SPSSInc., Chicago, IL, USA). One-way ANOVA (analysis of variance) with post-hoc test by Duncan’s multiple-range test was used to examine differences among groups. The data were analyzed by Student’s t-test for two group comparison.

**Results**

**Effect on PPARγ agonist**

To determine if the extract was a PPARγ agonist, we searched the cell-based GAL4/PPAR chimera transactivation in Hek293 cells. As shown in Figure 1A, the

**Figure 1 Extract functions as a PPARγ agonist.** (A) Extract increased the ligand-binding activity of PPARγ. Hek293 cells were transfected with pFA-PPARγ and pFR-Luc (UAS-Gal4-luciferase) and then treated with extract (5 μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours. (B) Extract induced transcriptional activity of PPARγ. Differentiated 3T3-L1 adipocytes were transfected with 3 × PPREs-tk-Luc and treated with extract (5 μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours. (C) Extract induced adipogenesis. Oil red O staining was measured after differentiation of 3T3-L1 cells in medium containing 0.1% DMSO (control), extract (5 μg/ml), rosiglitazone (1 μM), or macelignan (10 μM) for seven days. (D) Extract increased PPARγ target gene (aP2) expression in 3T3-L1 adipocytes. Differentiated 3T3-L1 cells were treated with extract (5 μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours. Expression of mRNAs was estimated using quantitative real-time RT-PCR, and the results were expressed as mRNA levels relative to 0.1% DMSO (control). Data represent are shown as mean ± SD of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
extract increased the PPARγ-dependent luciferase activity ($P = 0.035$ vs non-treatment) similar to that of rosiglitazone ($P = 0.001$ vs non-treatment), a well-known PPARγ agonist, and macelignan ($P = 0.005$ vs non-treatment), a PPARα/γ dual agonist used as positive control throughout the experiments. To further explore the PPARγ agonist potential of the extract, transient transfections were performed in differentiated 3T3-L1 adipocytes with the tk-luciferase vector containing PPAR-responsive elements (PPREs) and then treated with the extract. The treatment stimulated PPRE-dependent luciferase activities in transfected cells ($P = 0.005$ vs non-treatment) (Figure 1B). To provide biological evidence that the extract is a PPARγ ligand, we investigated adipocyte differentiation and expression of the adipocyte marker gene in 3T3-L1 cells treated with the extract. The treatment led to a significant increase in the formation of lipid droplets in similar to rosiglitazone and macelignan (Figure 1C). Moreover, the extract increased the expression of adipose fatty acid-binding protein (aP2) ($P = 0.042$ vs non-treatment) (Figure 1D). Taken together, these results demonstrated that the extract was a PPARγ agonist.

### Effect on AMPK activation

To determine if the extract mediated the AMP-activated protein kinase (AMPK) activation, we measured the AMPK phosphorylation and expression of fatty acid oxidation genes in C2C12 cells incubated with the extract. As with the AMPK activator, aminooimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) ($P = 0.001$ vs non-treatment), the treatment activated AMPK in C2C12 cells ($P = 0.007$ vs non-treatment), similar to when samples were treated with macelignan ($P = 0.042$ vs non-treatment) (Figure 2A). Consistent with the results of AMPK phosphorylation, the treatment increased the expression of acyl-CoA synthetase (ACS) ($P = 0.048$ vs non-treatment) and carnitine palmitoyltransferase-1 (CPT-1) ($P = 0.041$ vs non-treatment) (Figure 2B), suggest that the extract activated AMPK.

### Effect on inflammatory processes

As inflammatory processes play potential roles in the pathogenesis of insulin resistance, we investigated whether the extract possessed anti-inflammatory effects, including the inhibitory effects of the extract on IKKβ/NFκB signaling in HepG2 cells treated with TNF-α using NFκB response element containing reporter. While TNF-α treatment increased the NFκB-dependent luciferase activity ($P = 0.001$ vs non-treatment), The extract effectively prevented this increase ($P = 0.034$ vs TNF-α treatment) (Figure 3A).

---

**Figure 2** Extract activates AMPK in C2C12 cells. (A) Extract increased AMPK phosphorylation. C2C12 cells were treated with aminooimidazole-4-carboxamide-1-β-d-ribofuranoside (1 mmol/l), extract (5 μg/ml), or macelignan (10 μM) for 24 hours. Phosphorylated AMPK was examined by Western blot analysis. (B) Extract increased the mRNA expression of ACS, CPT-1. The expression was estimated using quantitative real-time RT-PCR. Data represent are shown as mean ± SD of three independent experiments (*$P < 0.05$, **$P < 0.01$, ***$P < 0.001$).

---
which was consistent with rosiglitazone and macelignan (Figure 3B). These results indicated that the extract exerted anti-inflammatory effects.

Effect on attenuation of ER stress

It has been recently suggested that ER stress plays a central role in the development of insulin resistance and diabetes by impairing insulin signaling through c-Jun NH2-terminal kinase (JNK) activation [16]. Therefore, diabetes by impairing insulin signaling through c-Jun central role in the development of insulin resistance and ER stress plays a effect on attenuation of ER stress. It has been recently suggested that ER stress plays a role in the development of insulin resistance and diabetes by impairing insulin signaling through c-Jun. Therefore, diabetes by impairing insulin signaling through c-Jun central role in the development of insulin resistance and ER stress plays a role in the development of insulin resistance and diabetes by impairing insulin signaling through c-Jun.

Effect on body weight change and fasting blood glucose in db/db mice

To examine the in vivo anti-diabetic effects of the extract on diabetes, we orally administered rosiglitazone (10 mg/kg), macelignan (15 mg/kg) and the extract (150 mg/kg) to C57BL/KsJ-db/db mice every day for three weeks and the extract's effects were compared with rosiglitazone and macelignan. Treatment with the extract did not have a significant effect on the body weights in the db/db mice; however, mice treated with rosiglitazone had final body weights significantly higher than those of the others (P = 0.001 vs control) (Figure 5A). The baseline (day 0) fasting blood glucose levels did not differ between groups; however, at the end of the experiment, the values of the extract-treated group were significantly lower compared to the diabetic control group (P = 0.022 vs control) and so did the other groups treated with rosiglitazone (P = 0.001 vs control) and macelignan (P = 0.002 vs control). The blood glucose levels of the extract-treated mice were significantly reduced by about 15% compared to the control (Figure 5B).

Effects on postprandial glucose and insulin sensitivity in db/db mice

To assess glucose homeostasis and insulin sensitivity in db/db mice treated with the extract, we performed glucose tolerance and insulin tolerance tests before the end of the experiment. As shown in Figure 6A, the extract significantly reduced the blood glucose levels (P = 0.001 vs control) similar to rosiglitazone (P = 0.003 vs control) and so did the other groups treated with rosiglitazone (P = 0.001 vs control) and macelignan (P = 0.004 vs control) used as positive controls compared with the diabetic control groups. The insulin tolerance test also showed that reduction in blood glucose levels in response to insulin was much greater in mice treated with the extract than in untreated db/db mice (P = 0.002 vs control) (Figure 6B). These findings indicate that treatment with the extract affected not only regulation of the postprandial glucose level, but also enhanced the insulin sensitivity.

Effects on plasma lipids in db/db mice

Effects of the extract on plasma triglycerides and FFAs levels and total cholesterol were investigated. Specifically, treatment with the extract significantly decreased the plasma free fatty acid (P = 0.021 vs control), triglyceride (P = 0.012 vs control) and total cholesterol (P = 0.003 vs control) concentrations of the diabetic control db/db mice compared with untreated db/db mice when the experiment ended (Table 1). As lipolysis and

\[ \text{Relative activity (% of non-treatment)} \]

\[ \text{Compound} \quad \text{TNF-\( \alpha \)} \quad \text{Non} \quad \text{Non} \quad \text{Ros} \quad \text{Mace} \quad \text{Extract} \]

\[ \begin{array}{cccc}
\text{TNF-\( \alpha \)} & \text{Non} & \text{Non} & \text{Ros} & \text{Mace} & \text{Extract} \\
\end{array} \]

\[ \text{I\( \kappa \)B\( \alpha \)} & \text{Non} & \text{TNF-\( \alpha \)} & \text{Ros} & \text{Mace} & \text{Extract} \\
\end{array} \]

\[ \text{\( \beta \)-actin} \]

Figure 3 Extract inhibits NFkB signaling in HepG2 cells.

(A) extract prevented the increase of TNF-\( \alpha \)-stimulated luciferase activity in TNF-\( \alpha \)-treated HepG2. HepG2 cells were transfected with NFkB-Luc reporter and then treated with extract (5 \( \mu \)g/ml), rosiglitazone (10 \( \mu \)M), or macelignan (10 \( \mu \)M) for 24 hours in the presence of TNF-\( \alpha \) (10 ng/ml) (B) extract increased the IkB level. HepG2 cells were transfected with extract (5 \( \mu \)g/ml), rosiglitazone (10 \( \mu \)M), or macelignan (10 \( \mu \)M) for 24 hours and then treated with TNF-\( \alpha \) (10 ng/ml) for one hour. IkB\( \alpha \) was measured by Western blot analysis. Data represent are shown as mean ± SD of three independent experiments (\( * \)P < 0.05, \( ** \)P < 0.01, ***P < 0.001).
circulating free fatty acids increase under insulin resistance conditions, these results demonstrate that the decrease in plasma lipids may contribute to the improvement of severe diabetes, at least partially.

Effects on glycosylated hemoglobin level and plasma biomarkers in db/db mice
Mice receiving the treatment with the extract showed a significantly lower blood glycosylated hemoglobin level compared to the diabetic control db/db mice ($P = 0.002$ vs control). Both the plasma insulin ($P = 0.042$ vs control) and C-peptide levels ($P = 0.038$ vs control) were significantly higher in the extract-treated db/db mice than in the diabetic control db/db mice; however, the glucagon levels were significantly lower than those of the diabetic control db/db mice ($P = 0.018$ vs control). Therefore, treatment with the extract significantly improved the ratio of insulin/glucagon (I/G) when compared to the diabetic control db/db mice (Table 2).

Discussion
In this study, we tested a formulation of seven medicinal herbs including Panax ginseng C.A.Meyer for the antidiabetic effects in cells and in vivo. We found that the extract from the seven herbs functioned as PPARγ agonists and an AMPK activators, as well as inhibitors of inflammation and ER stress. PPARγ can improve insulin sensitivity and glucose tolerance by regulating lipid storage, glucose homeostasis and adipokine regulation [17]. The TZD group, especially rosiglitazone and troglitazone, are agonists of PPARγ [18]. The extract significantly increased the PPARγ-dependent luciferase activity in vitro and stimulated the formation of lipid droplets and the expression of aP2 upon transient transfection of 3T3-L1 cells. Rb1, the most abundant ginsenoside in ginseng root, increases the expression of mRNA and protein of PPARγ and exerts anti-diabetic and insulin-sensitizing activities [19]. 20(S)-protopanaxatriol (PPT), a ginsenoside metabolite, increases PPARγ-transactivation activity.
with an activity similar to troglitazone, and up-regulates
the expression of PPARγ target genes such as aP2, LPL
and PEPCK [15]. Therefore, the activity of PPARγ against
may be due to Panax ginseng. Further studies are
required to confirm this speculation.

Activation of AMPK enhances insulin sensitivity
through increased glucose uptake and lipid oxidation in
skeletal muscle and inhibition of glucose and lipid
synthesis in the liver [20]. Metformin acts as an activa-
tor of AMPK in the liver and skeletal muscle [21]. The
present study demonstrated that the extract activated
AMPK in C2C12 and induced increased expression of
AMPK target genes. Ginsenoside Rh2 and Rg3, a red
ginseng rich constituent, activates AMPK significantly in
3T3-L1 adipocytes and to contribute to antiobesity effects [22,23]. Further studies are required to characterize which herb activates AMPK.

Inflammatory cytokines and IKK attenuate insulin signaling through serine phosphorylation of IRS-1 [24]. High doses of salicylates, which block the IKKb activity, ameliorate hyperglycemia and insulin resistance in diabetes and obesity [25]. Our results showed that the extract effectively suppressed NFkB-dependent luciferase activity in TNF-α-treated HepG2 cells and increased the IkB level, suggesting that the extract blocked the activation of the NF-κB pathways.

By activating c-Jun amino-terminal kinase (JNK), which induces insulin resistance in liver and skeletal
Table 1 Effects of the extract on the plasma lipid profiles in db/d b mice

|                  | Control       | Rosiglitazone | Macelignan   | Extract       |
|------------------|---------------|---------------|--------------|---------------|
| FFAs (mmol/L)    | 2.28 ± 0.21a  | 0.94 ± 0.05c  | 1.70 ± 0.21b | 1.75 ± 0.11b  |
| Triglyceride (mg/dL) | 296 ± 59.5a  | 109.4 ± 29.2c | 2590 ± 54.9b | 217.9 ± 34.9b |
| Total cholesterol (mg/dL) | 146.1 ± 15.0b | 181.9 ± 5.84a | 1100 ± 22.4c | 119.4 ± 3.41c |

Data in the same row not sharing a common superscript indicate a significant difference (P < 0.05) between groups after one-way ANOVA and Duncan's multiple-range test; mean ± SD (n = 7); FFAs: free fatty acids.

Table 2 Effects of the extract on concentrations of blood and plasma biomarkers in db/db mice

|                  | HbA1c (%) | Insulin (ng/mL) | Glucagon (ng/mL) | C-peptide (ng/mL) | I/G |
|------------------|-----------|----------------|-----------------|-----------------|-----|
| Control          | 10.7 ± 0.46a | 1.48 ± 0.89b | 0.37 ± 0.07b     | 3.12 ± 0.73b     | 4.68 ± 1.11b |
| Rosiglitazone    | 7.40 ± 0.88a | 3.43 ± 1.05a  | 0.32 ± 0.02a     | 4.76 ± 1.09a     | 9.67 ± 3.05ab |
| Macelignan       | 10.8 ± 0.25a | 1.52 ± 0.12b  | 0.23 ± 0.05b     | 4.14 ± 0.35ab    | 6.74 ± 1.31b  |
| Extract          | 9.3 ± 0.80b  | 3.15 ± 1.43a  | 0.21 ± 0.02b     | 4.79 ± 0.44a     | 14.2 ± 7.55a  |

Data in the same row not sharing a common superscript indicate a significant difference (P < 0.05) between groups after one-way ANOVA and Duncan's multiple-range test; mean ± SD (n = 7); HbA1c: blood glycosylated hemoglobin; I/G: ratio of insulin/gluca gon.

muscle and inhibits beta cell function, ER stress induces the development of type 2 diabetes [26]. Thus, agents that alleviate ER stress may act as potent anti-diabetic agents. Chemical or biological compounds such as macelignan [27], chromium-phenylalanine [28], PBA (phenyl butyric acid) [29] or TUDCA (tauroursodeoxycholic acid) [30] or molecular chaperon have been shown to inhibit ER stress and enhance insulin sensitivity, thereby normalizing hyperglycemia. The present study found that the extract alleviated ER stress and efficiently suppressed ERSE-dependent transactivation in thapsigargin-treated HepG2 and expression of ER stress marker proteins. In future studies, we will determine the optimal combination ratio for this formulation and isolate its active fractions.

Conclusion

The aqueous extract of these seven hypoglycemic herbs demonstrated anti-diabetic effects on type 2 diabetes.

Abbreviations

ACS: acyl-CoA synthetase; AICAR: aminomimidazole carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; apo2: adipose fatty acid-binding protein 2; CPT-1: carnitine palmitoyltransferase-1; DMSO: Dimethylsulfoxide; ER: endoplasmic reticulum; ERSE: ER stress response element; FFAs: free fatty acids; eIF: elongation initiation factor; GLP-1: glucagon-like peptide-1; HbA1c: blood glycosylated hemoglobin; HDL-cholesterol: high density lipoprotein-cholesterol; Hex293: human embryonic kidney293; IKK: IκB kinase; IPGTT: intraperitoneal glucose tolerance test; IPITT: intraperitoneal insulin tolerance test; JNK: c-Jun N-terminal kinases; LPL: lipoprotein lipase; OAD: oral antidiabetic drug; PBA: phenyl butyric acid; PPAR: peroxisome proliferator-activated receptor; PPRPR: PPAR-responsive elements; SD: standard deviation; Tzd: thi azolidinedione

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (331-2008-1-E-00036) and Pusan National University (Program Post-Doc 2009).

Authors’ contributions

MHJ designed the study and wrote the manuscript. SIC prepared the aqueous extract from the herbs. YJY conducted the in vivo experiments. YMK conducted the experiments in cultured cells. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 14 October 2010 Accepted: 4 March 2011 Published: 4 March 2011

References

1. Chan JY, Leung PC, Che CT, Fung KP: Protective effects of an herbal formulation of Radix Astragali, Radix Codonopsis and Cortex Lycii on streptozotocin-induced apoptosis in pancreatic beta-cells: an implication for its treatment of diabetes mellitus. Phytother Res 2008, 22:190-196.
2. Colberg SR, Zarrabi L, Bennington L, Nakave A, Thomas SC, Swain DP, Sechrist SR: Postprandial walking is better for lowering the glycemic effect of dinner than pre-dinner exercise in type 2 diabetic individuals. J Am Med Diet Assoc 2009, 10:394-397.
3. Yin J, Zhang H, Ye J: Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008, 8:99-111.
4. Bailey CI, Day C: Traditional plant medicines as treatments for diabetes. Diabetes care 1989, 12:553-564.
5. Bansky D, Barolet R: Chinese Herbal Medicine Formulas and Strategies Seattle: Eastland Press; 1990, 3-14.
6. Li W, Zheng HC, Bukuru J, De Kimpe N: Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004, 92(1):29-41.
7. Hui H, Tang G, Go VL: Hypoglycemic herbs and their action mechanisms. Chin Med 2009, 4:11.
8. Waisundara VY, Huang M, Hsu A, Huang D, Tan BK: Characterization of the anti-diabetic and antioxidant effects of Rehmannia Glutinosa in streptozotocin-induced diabetic wistarats. Am J Chin Med (Card City N Y) 2008, 36:1083-1104.
9. Suneetha WJ, Krishnakantha TP: Poncirus trifoliata fruit extract. Phytother Res 2006, 20:437-440.
10. Lee YM, Kim DK, Kim SH, Shin TY, Kim HM: Antianaphylactic activity of Poncirus trifoliate fruit extract. J Ethnopharmacol 1996, 54:77-84.
11. Yamahara J, Yamada T, Kitani T, Naitoh Y, Fujimura H: Antinociceptive action and active constituents of eudoxiae fructus. Chem Pharm Bull (Tokyo) 1989, 37:1820-1822.
12. Korea Food & Drug Administration, Republic of Korea: The Korean Pharmacopeia. Seoul; 2008, 942-974.
13. Chung JY, Choo JH, Lee MH, Hwang JK. Anticariogenic activity of macelignan isolated from Myristica fragrans (nutmeg) against Streptococcus mutants. *Phytomedicine* 2006, 13:261-266.

14. Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK, Do MS. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. *Exp Mol Med* 2006, 38:599-605.

15. Han KL, Jung MH, Sohn JH, Hwang JK. Ginsenoside 20(S)-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes. *Biol Pharm Bull* 2006, 29:110-113.

16. Fonseca SG, Burcin M, Gromada J, Urano F. Endoplasmic reticulum stress in beta-cells and development of diabetes. *Curr Opin Pharmacol* 2009, 9:763-770.

17. Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ. Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. *PPAR Res* 2008, 581348:1-9.

18. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. *J Lipid Res* 2002, 43:1809-1817.

19. Han KL, Jung MH, Song J, Joe MK, Jung MH, Hwang JK. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. *Diabetes* 2008, 57:737-745.

20. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumour necrosis factor-treated cells through targeting multiple serine kinases. *J Biol Chem* 2003, 278:24944-24950.

21. Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Miyatsuka T, Matsuhisa M, Yamasaki Y. Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. *J Mol Med* 2005, 83:429-439.

22. Sreejayan N, Dong F, Kandadi MR, Yang X, Ren J. Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. *Obesity* 2008, 16:1331-1337.

23. Ozcak U, Yilmaz E, Ozcak L, Furushali M, Vaillioncourt E, Smith RO, Gorgun CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. *Science* 2006, 313:1137-1140.

24. Xie Q, Khatsanov V, Chung CC, Sohn J, Krishnan B, Lewis DE, Yoffie B. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. *Hepatology* 2002, 36:592-601.

doi:10.1186/1749-8546-6-10

cite this article as: Yeo et al. Effects of a multi-herbal extract on type 2 diabetes. *Chinese Medicine* 2011 6:10.